ASCO GU 2019 Bladder Cancer - Results from #20

Viewing 21-26 of 26 articles

ASCO GU 2019: Genomic Insights and Biomarkers for Treatment Selection in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer

ASCO GU 2019: Immunotherapy Across Genitourinary Malignancies

ASCO GU 2019: TROPHY-u-01: A Phase II Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Patients with Advanced Urothelial Cancer after Progression on Platinum-Based Chemotherapy and/or Anti-PD-1/PD-L1 Checkpoint Inhibitor Therapy

ASCO GU 2019: Randomized Phase III Trial of Adjuvant Sequential Chemotherapy Plus Radiotherapy versus Adjuvant Radiotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy

ASCO GU 2019: Keynote 057: Phase II trial of Pembrolizumab for Patients with High-risk NMIBC Unresponsive to BCG: Updated Interim Results

ASCO GU 2019: Long-term Outcomes of Hypoxia Modification in Bladder Preservation: Update from BCON Trial

1
2